These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32100879)

  • 1. Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma.
    Akuta N; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Suzuki Y; Kumada H
    J Med Virol; 2020 Dec; 92(12):3604-3608. PubMed ID: 32100879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
    Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
    Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma.
    Trung NT; Hoan NX; Trung PQ; Binh MT; Van Tong H; Toan NL; Bang MH; Song LH
    Sci Rep; 2020 May; 10(1):8181. PubMed ID: 32424223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
    Cevik D; Yildiz G; Ozturk M
    World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of Cell-Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy.
    Muraoka M; Maekawa S; Katoh R; Komiyama Y; Nakakuki N; Takada H; Matsuda S; Suzuki Y; Sato M; Tatsumi A; Miura M; Amemiya F; Shindo H; Takano S; Fukasawa M; Yamauchi K; Yamaguchi T; Nakayama Y; Inoue T; Enomoto N
    Hepatol Commun; 2021 Nov; 5(11):1927-1938. PubMed ID: 34558819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.
    Yang X; Guo X; Chen Y; Chen G; Ma Y; Huang K; Zhang Y; Zhao Q; Winkler CA; An P; Lyu J
    Oncotarget; 2016 May; 7(19):27838-47. PubMed ID: 27056898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Detecting Low Prevalence Somatic
    da Costa VR; Bim LV; Pacheco E Silva LDP; Colloza-Gama GA; Bastos AU; Delcelo R; Oler G; Cerutti JM
    Front Endocrinol (Lausanne); 2021; 12():643151. PubMed ID: 33776938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma.
    Ako S; Nouso K; Kinugasa H; Matsushita H; Terasawa H; Adachi T; Wada N; Takeuchi Y; Mandai M; Onishi H; Ikeda F; Shiraha H; Takaki A; Fujioka S; Mimura T; Okada H
    Oncology; 2020; 98(5):311-317. PubMed ID: 32135540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
    Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
    Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Pedersen MH; Weber B; Aagaard NK; Villadsen GE; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    Scand J Gastroenterol; 2020 Dec; 55(12):1433-1440. PubMed ID: 33103505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
    Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
    Liu T; Brown TC; Juhlin CC; Andreasson A; Wang N; Bäckdahl M; Healy JM; Prasad ML; Korah R; Carling T; Xu D; Larsson C
    Endocr Relat Cancer; 2014 Jun; 21(3):427-34. PubMed ID: 24803525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
    Nault JC; Calderaro J; Di Tommaso L; Balabaud C; Zafrani ES; Bioulac-Sage P; Roncalli M; Zucman-Rossi J
    Hepatology; 2014 Dec; 60(6):1983-92. PubMed ID: 25123086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
    Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
    Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
    Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
    Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.
    Tang Q; Hu G; Sang Y; Chen Y; Wei G; Zhu M; Chen M; Li S; Liu R; Peng Z
    Clin Transl Med; 2024 May; 14(5):e1703. PubMed ID: 38769666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatial Distribution Patterns of Clinically Relevant TERT Promoter Mutations in Follicular Thyroid Tumors of Uncertain Malignant Potential: Advantages of the Digital Droplet PCR Technique.
    Hysek M; Jatta K; Hellgren LS; Stenman A; Larsson C; Zedenius J; Juhlin CC
    J Mol Diagn; 2021 Feb; 23(2):212-222. PubMed ID: 33197629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma.
    Adachi JI; Shirahata M; Suzuki T; Mishima K; Uchida E; Sasaki A; Nishikawa R
    Brain Tumor Pathol; 2021 Jul; 38(3):201-209. PubMed ID: 34128111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.
    Lee HW; Park TI; Jang SY; Park SY; Park WJ; Jung SJ; Lee JH
    Medicine (Baltimore); 2017 Feb; 96(5):e5766. PubMed ID: 28151853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.